



Biotech Daily

SPECIAL SUMMER CATCH-UP EDITION

Sunday, January 16, 2022

The Summer Catch-Up Edition was compiled by Noah Nicholas

- * TELIX: FDA APPROVES ILLUCCIX FOR PROSTATE CANCER IMAGING
- * PHARMAXIS 'OVERSUBSCRIBED' PLAN RAISES \$2.6m; TOTAL \$9.8m
- * ACTINOGEN SHARE PLAN RAISES \$1.3m; TOTAL \$13.3m
- * AVECHO, MEDTERRA MARIJUANA DISTRIBUTION DEAL
- * CHAIR RON DEWHURST, KROY WEN TAKE 6.83% OF RHINOMED
- * INCANNEX: PHASE II IHL-42X MARIJUANA OSA DOSING COMPLETE
- * RESONANCE: EX00A31 REDUCES HEPATITIS B REPLICATION IN-VITRO
- * CLINUVEL: FDA OKAYS PHASE II SCENESSE FOR VITILIGO STUDY
- * INVEX RECEIVES \$186k UK R&D TAX REBATE
- * CSL SHARE PLAN TO RAISE \$750m
- * TELIX: 1st PATIENT DOSED IN PHASE I BLADDER CANCER TRIAL
- * GENETIC SIGNATURES: VARIANT KIT DIFFERENTIATES DELTA,OMICRON
- * FORMER CHAIR RAY BLIGHT INCREASES, DILUTED TO 8% OF ALCIDION
- * DIRECTOR PROF MALCOLM PRADHAN DILUTED TO 8% OF ALCIDION
- * RHINOMED: RHINOSWAB JUNIOR MEETS EQUIVALENCE ENDPOINT
- * COGSTATE PROMOTED TO S&P ASX ALL TECHNOLOGY INDEX
- * RACE SHARE PLAN RAISES \$29.7m; DR TILLET INCREASE, DILUTED
- * BIONOMICS NASDAQ IPO RAISES \$28m
- * LUMOS: CANADA ORDERS \$350k COVIDX SARS-COV-2 RAPID TESTS
- * AUDEARA APPOINTS AUDIKA AUSTRALIA DISTRIBUTOR
- * IMEX: COLOMBIA POLICE \$1.1m RADIOLOGY CONTRACT

- * MGC STARTS ARTEMIC 'LONG COVID' PILOT STUDY
- * NEUROSCIENTIFIC: 'EMTIN PEPTIDES MODULATE INFLAMMATION IN-VITRO'
- * NIV DAGAN TAKES 11.38% OF INHALERX
- * TOTAL BRAIN PAYS \$3.1m FOR JANSSEN DEPRESSION RESEARCH
- * ANTISENSE SHARE PLAN RAISES \$2.6m; TOTAL \$22.6m
- * CYNATA STARTS PHASE I CYP-006TK DIABETIC FOOT ULCER TRIAL
- * PLATINUM INCREASES, DILUTED TO 15% OF AMPLIA
- * DIMERIX RECEIVES FEDERAL \$100k GRANT
- * PLATINUM TAKES 17% OF ADALTA
- * AUSTRALIAN SUPER TAKES 9.5% OF ALCIDION
- * MICRO-X RECEIVES \$2.1m R&D TAX INCENTIVE
- * RESAPP APPOINTS SANRAI 'EMERGING MARKETS' DISTRIBUTOR
- * SIO INCREASES, DILUTED TO 12.6% OF ANTERIS
- * FIL BELOW 5% OF COGSTATE
- * MARK LAMPERT, BVF INCREASE, DILUTED TO 13% OF BIONOMICS
- * SHENGLI WANG DILUTED TO 10.63% OF INVION
- * LUMOS VIRADX RAPID TEST SUBMISSIONS READY; ELLERSTON BELOW 5%
- * REGENEUS \$800k R&D INCENTIVE; JAPAN PROGENZA PATENT
- * ANTEOTECH RECEIVES \$1.96m R&D TAX INCENTIVE
- * EXOPHARM US PATENT FOR LEAP EXOSOME PRODUCTION
- * NYRADA PHASE I CHOLESTEROL DRUG TRIAL IN LATE-2022
- * AVITA AGM: 42% OPPOSE EXECUTIVE COMPENSATION
- * DIMERIX APPROVAL FOR AUSTRALIAN PILOT/PHASE III COVID STUDY
- * NUHEARA \$4.6m PLACEMENT, RIGHTS OFFER FOR \$3m
- * PERENNIAL REDUCES TO 7.55% OF MEDADVISOR
- * RESPIRI, M-TELEHEALTH SIGN 5-YEAR, \$210k DEAL FOR WHEEZO IN THE US
- * ONCOSIL: LOCAL PANCREATIC CANCER CONTROL IN 90.5% OF PATIENTS
- * YUUWA DILUTED TO 18.2% OF ADALTA

- * INVIQ (BARD1): CHINA PATENT FOR LUNG CANCER DIAGNOSIS
- * UNIVERSAL BIOSENSORS \$50k PA FOR IQ SCIENCE APTAMERS
- * PARADIGM 2nd STRIKE, 80% DIRECTORS FEEL POOL HIKE; 525k SHARES
- * CITIGROUP TAKES 22.3% OF BIONOMICS
- * PERENNIAL TAKE 11.5% OF LUMOS
- * STEMCELL FURTHER EXTENDS 'JOINT VENTURE' SUSPENSION
- * ANDREW CHAPMAN, MERCHANT BELOW 5% OF RACE
- * CYNATA, FUJIFILM MANUFACTURING DEAL
- * ALCIDION RIGHTS RAISE \$11.6m; TOTAL \$55m
- * ANTERIS OPTIONS RAISE \$18.9m
- * LBT ACQUIRES HETTICH'S 50% OF CLEVER CULTURE SYSTEMS
- * OSTEOPORE: MARK LEONG EXECUTIVE CHAIR; VLADO BOSANAC DIRECTOR
- * LIVING CELL RIGHTS RAISE \$361k; \$3.4m SHORTFALL
- * CANN GLOBAL AGM: \$312k SHARES FOR EX-CHAIR PNINA FELDMAN
- * CARL CHARALAMBOUS TAKES 7.23% OF EXOPHARM
- * DARRYL DAVIES REPLACES INHALERX CEO MATTHEW GOLDEN
- * EX-DIRECTOR BERNARD HOCKINGS REDUCES TO 6.3% OF PYC
- * TOTAL BRAIN \$692k ALTO NEUROSCIENCE ISPOT-D DATA DEAL
- * RESONANCE FDA CLEARANCE FOR LIVERSMART
- * ATOMO PLEADS SCHULTZ, MEDIA, RATS TO ASX 36% PRICE QUERY
- * ASIA PACIFIC HEALTHCARE INVESTMENTS TAKES 6% OF CLARITY
- * TRAJAN PAYS \$7m, 4.7m SHARES FOR NEOTERYX BLOOD MICRO-SAMPLING
- * EMYRIA APPOINTS SIXTY TWO CAPITAL ADVISER
- * MESOBLAST TO FILE NEW REMESTEMCEL-L POTENCY DATA TO FDA
- * TRAJAN COMPLETES LEAP ACQUISITION
- * PERENNIAL BELOW 5% IN NUHEARA
- * BIONOMICS LOSES BVF PARTNERS NOMINEE DIRECTOR MITCHELL KAYE
- * ECOFIBRE EXTENDS LOAN TERMS

- * M-D ROBERT WONG TAKES 6.79% OF CONTROL BIONICS
- * OPTHEA APPOINTS EX-DIRECTOR JUDITH ROBERTSON CCO
- * IMUGENE COMPLETES PHASE Ia PD1-VAXX MONOTHERAPY DOSING
- * IMUGENE APPOINTS URSULA MCCURRY, DR NIMALI WITHANA EXECUTIVES
- * ALTERITY LOSES DIRECTORS DR DAVID SINCLAIR, TRISTAN EDWARDS
- * HETTICH TAKES 9.6% OF LBT
- * BIONOMICS STARTS PHASE II BNC-210 SOCIAL ANXIETY TRIAL
- * CHRISTIAN ANGEMAYER, APEIRON TAKE 19.9% OF BIONOMICS
- * HEXIMA APPOINTS PHILLIP ROSE US CHIEF COMMERCIAL OFFICER
- * IMRICOR: ATHENS' HENRY DUNANT HOSPITAL BUYS ABLATION PRODUCTS
- * ISLAND HIRES ICON FOR PHASE II ISLA-101 DENGUE FEVER TRIAL
- * ANTERIS APPLIES FOR ADAPT STERILISATION PATENT
- * CRONOS PLEADS SCHULTZ, 'CDA MERGER TO ASX 42% PRICE QUERY
- * DR GISELA MAUTNER REPLACES NOXOPHARM CEO, M-D DR GRAHAM KELLY
- * PHARMAXIS: NHMRC \$1.4m FOR DRUG PIPELINE RESEARCH
- * ALTERITY: US PATENT FOR NEURO-DEGENERATIVE DISEASE
- * IMUGENE: SOUTH KOREA PATENT FOR HER-VAXX
- * NUHEARA COMPLETES HEARING AID CLINICAL TRIAL
- * RHYTHM: \$6.53m PLACEMENT TO UNNAMED 'GLOBAL FUNDS MANAGER'
- * CITIGROUP TAKES 24.73% OF BIONOMICS
- * IMUGENE RECEIVES \$6.54m FEDERAL R&D TAX INCENTIVE
- * FEDERAL \$15m FOR PSYCHEDELICS FOR MENTAL HEALTH
- * ISRAEL'S REDHILL APPOINTS GAELAN EMIRATES TALICIA DISTRIBUTOR
- * AVITA: 'PROOF-OF-CONCEPT FOR GM SKIN CELLS'
- * AVITA: RECELL SOFT-TISSUE RECONSTRUCTION TRIAL ENROLLED
- * MESOBLAST: 1.7m US WARRANTS FOR OAKTREE LOAN FACILITY
- * RESAPP: RESAPDX ON ALODOKTER TELEHEALTH PLATFORM
- * RECCE: POSITIVE SAFETY DATA FROM PHASE I R327 TRIAL

- * CRESO TO RELEASE 47m SHARES FROM VOLUNTARY ESCROW
- * MGC: INDIA GRANTS ARTEMIC RESCUE IMPORT APPROVAL
- * NOXOPHARM RECEIVES \$5.9m FEDERAL R&D TAX INCENTIVE
- * PHARMAXIS TELLS ASX: 'NHMRC GRANTS NOT MATERIAL'
- * GENETIC SIGNATURES: TGA REGISTERS SARS-CoV-2 SALIVA PROTOCOL
- * RESAPP COMPLETES US COVID-COUGH STUDY RECRUITMENT
- * INOVIQ \$89k FOR SUBB2M TEST ANTIBODIES
- * CHELSEA SHERIDA REPLACES BLUECHIP CO SEC LEE MITCHELL
- * RACE CHAIR DR JOHN CULLITY SELLS 300k SHARES
- * ZELIRA RECEIVES \$348k FROM DRCN
- * POLYNOVO H1 REVENUE UP 43% TO \$18.04m
- * DIMERIX DOSES 1st DMX-200 COVID-19 PATIENTS IN INDIA
- * KIM BRADLEY REPLACES CRYOSITE CHAIR BRYAN DULHUNTY AS CO SEC
- * CRESO: HALUCENEX APPLIES FOR CANADA SPECIAL ACCESS PROGRAM
- * BCAL APPOINTS DR JOHN HURRELL CEO; STARTS ON \$300k
- * BLACKROCK TAKES 12.2% OF IMRICOR
- * SDI H1 REVENUE UP 26% TO \$46m
- * COMPUMEDICS H1 ORDERS UP 33%, REVENUE DOWN 7% TO \$17m
- * COMPUMEDICS \$4.2m ORION LIFESPAN SALE TO TIANJIN NORMAL UNI
- * MESOBLAST: REXLEMESTROCEL-L PROVIDES 3-YEAR LOWER BACK RELIEF
- * KKR CORE INVESTORS TAKES 6% OF CLARITY
- * IMMURON: \$6.2m FOR US MILITARY-GRADE TRAVELAN FOR DIARRHOEA
- * LIVERPOOL PHARMACIES ADOPT LUMOS FEBRIDX
- * ZELIRA RECEIVES \$1.2m FEDERAL R&D TAX INCENTIVE
- * MAYNE TO SELL GENERIC PROTOPIC FOR ECZEMA IN US
- * NYRADA RECEIVES \$1.3m FEDERAL R&D TAX INCENTIVE
- * FEDERAL \$25.6m FOR CYNATA, ACRUX, AXIAL
- * PARADIGM DOSES 1st PHASE III OSTEO-ARTHRITIS PPS PATIENTS

- * **AMPLIA COMPLETES AMP945 MANUFACTURE FOR TRIALS**
- * **ADHERIUM: US FINALISES REMOTE THERAPEUTIC MONITORING CPT CODES**
- * **IMMURON: EU PATENT FOR TRAVELLER'S DIARRHOEA**
- * **ARGENICA APPOINTS DR MEGHAN THOMAS CLINICAL DEVELOPMENT HEAD**
- * **ARTRYA APPOINTS DR JACQUE SOKOLOV ADVISOR BOARD CHAIR**
- * **KOSMAS DIMITRIOU REPLACES IQ3 CO SEC RON HOLLANDS**
- * **KORDA MENTHA REQUESTS BIDS FOR PALLA**
- * **REDHILL: OPAGANIB IMPROVES COVID-19 VIRAL RNA CLEARANCE**
- * **MTP CONNECT AWARDS 10 FELLOWSHIPS**
- * **MTP CONNECT: \$20m FOR DIABETES, CARDIOVASCULAR DISEASE**
- * **CARDIEX 1-FOR-10 CONSOLIDATION EGM**
- * **EVERCORE TAKES 22% OF BIONOMICS**
- * **AROVELLA (SUDA) LOSES EXECUTIVE DIRECTOR DAVID PHILLIPS**
- * **STEMCELL FURTHER EXTENDS 'JOINT VENTURE' SUSPENSION**

Detailed summaries continue on the following pages

The following articles appear in date order

Monday December 20, 2021

TELIX: FDA APPROVES ILLUCCIX FOR PROSTATE CANCER IMAGING

[TELIX PHARMACEUTICALS](#)

Telex says the US Food and Drug Administration has approved its Illucix prostate cancer imaging product.

The company said Illuccix was "the first commercially available FDA-approved product to enable wide accessibility to 68Ga-based PSMA-PET imaging for physicians and eligible patients in the US".

PHARMAXIS 'OVERSUBSCRIBED' PLAN RAISES \$2.6m; TOTAL \$9.8m

[PHARMAXIS](#)

Pharmaxis says it has raised \$2,585,000 in an oversubscribed share plan, taking the total raised to \$9.8 million.

ACTINOGEN SHARE PLAN RAISES \$1.3m; TOTAL \$13.3m

[ACTINOGEN MEDICAL](#)

Actinogen says it raised \$1,322,500 of a hoped-for \$3 million in a share purchase plan, taking the total raised to \$13,322,500.

AVECHO, MEDITERRA MARIJUANA DISTRIBUTION DEAL

[AVECHO BIOTECHNOLOGY](#)

Avecho says the Irvine, California Medterra will pay up-to \$US850,000 (\$A1,199,000) and two percent royalties to distribute its marijuana cannabidiol soft-gel capsules. Avecho said Medterra would develop and commercialise the capsules for arthritis, with a view to US approval and have exclusive rights outside Australia and New Zealand.

CHAIR RON DEWHURST, KROY WEN TAKE 6.83% OF RHINOMED

[RHINOMED](#)

Rhinomed chair Ron Dewhurst and Kroy Wen say they have increased and been diluted from 8,700,000 shares (5.14%) to 17,750,000 shares or (6.83%).

INCANNEX: PHASE II IHL-42X MARIJUANA OSA DOSING COMPLETE

[INCANNEX hHEALTHCARE](#)

Incannex says it has completed dosing patients in a phase II proof-of-concept trial of its marijuana combination product IHL-42X for obstructive sleep apnoea.

RESONANCE: EX00A31 REDUCES HEPATITIS B REPLICATION IN-VITRO

[RESONANCE HEALTH](#)

Resonance says its EX00A31 antisense oligonucleotide significantly reduces both DNA replication and surface antigen secretion in a cell model of hepatitis B. Resonance said that it would test EX00A31 against hepatitis B and C in mice.

CLINUVEL: FDA OKAYS PHASE II SCENESSE FOR VITILIGO STUDY

[CLINUVEL PHARMACEUTICALS](#)

Clinuvel says the US Food and Drug Administration has approved a six-month phase II study of Scenesse as a monotherapy for vitiligo in patients “with darker skin”.

INVEX RECEIVES \$186k UK R&D TAX REBATE

[INVEX THERAPEUTICS](#)

Invex says it has received GBP100,000 (\$A186,000) in a research and development tax rebate from the UK government for the 2021 financial year.

Tuesday December 21, 2021

CSL SHARE PLAN TO RAISE \$750m

[CSL](#)

CSL says it hopes a share plan will raise \$750 million, to follow its \$6.3 billion placement to acquire Vifor Pharma for \$US12.3 billion (BD: Dec 14, 2021).

TELIX: 1st PATIENT DOSED IN PHASE I BLADDER CANCER TRIAL

[TELIX PHARMACEUTICALS](#)

Telix says it has dosed its first patient in a phase I investigator-led, open-label study of safety, distribution and dosing of its TLX250-CDx alpha emitter for bladder cancer.

GENETIC SIGNATURES: VARIANT KIT DIFFERENTIATES DELTA,OMICRON

[GENETIC SIGNATURES](#)

Genetic Signatures says that its research use only Easyscreen Sars-Cov-2 variant detection kit can differentiate between the Delta and Omicron variants of the virus.

FORMER CHAIR RAY BLIGHT INCREASES, DILUTED TO 8% OF ALCIDION

[ALCIDION](#)

Former chair Ray Blight and spouse Gail Morris say they have increased but been diluted from 100,578,081 shares (10.15%) to 101,871,831 shares (7.99%) of Alcidion.

DIRECTOR PROF MALCOLM PRADHAN DILUTED TO 8% OF ALCIDION

[ALCIDION](#)

Alcidion executive director Prof Malcolm Pradhan says his 134,582,403 shares have been diluted from 13.58 percent to 10.55 percent of the company.

RHINOMED: RHINOSWAB JUNIOR MEETS EQUIVALENCE ENDPOINT

[RHINOMED](#)

Rhinomed says that a 254-patient trial of Rhinoswab Junior has met its primary endpoint of laboratory equivalence to throat and nose swabs.

Rhinomed said the trial was run by the Murdoch Children's Research Institute at Melbourne's Royal Children's Hospital.

COGSTATE PROMOTED TO S&P ASX ALL TECHNOLOGY INDEX

[STANDARD & POOR'S DOW JONES INDICES, COGSTATE](#)

Standard & Poor's said Cogstate has been promoted to its ASX all technology index.

RACE SHARE PLAN RAISES \$29.7m; DR TILLET INCREASE, DILUTED

[RACE ONCOLOGY](#)

Race says it has raised \$29.7 million in a 'heavily oversubscribed' share purchase plan which received \$43.9 million in applications for shares at \$3.00 each.

Separately, Race executive director Dr Daniel Tillett said his holding had increased and been diluted from 13,450,000 shares (9.72%) to 13,480,000 shares (8.45%).

BIONOMICS NASDAQ IPO RAISES \$28m

[BIONOMICS](#)

Bionomics says it has raised approximately \$US20 million (\$A28 million) in an initial public offering of 1,622,000 American depository shares on the NASDAQ.

LUMOS: CANADA ORDERS \$350k COVIDX SARS-COV-2 RAPID TESTS

[LUMOS DIAGNOSTICS](#)

Lumos says Health Canada has ordered \$US250,000 (\$A350,000) of its severe acute respiratory syndrome coronavirus-2 (Sars-Cov-2) rapid antigen tests and it expects further orders to follow in 2022.

AUDEARA APPOINTS AUDIKA AUSTRALIA DISTRIBUTOR

[AUDEARA](#)

Audeara says it has appointed Sydney's Audika to distribute its personalized audio headphones to more than 350 clinics in Australia.

IMEX: COLOMBIA POLICE \$1.1m RADIOLOGY CONTRACT

[IMEX HEALTH SERVICES](#)

Imexhs says it has a contract worth \$1.1 million in annual recurring revenue to outsource the Colombian National Police Force's radiology department.

MGC STARTS ARTEMIC ‘LONG COVID’ PILOT STUDY

[MGC PHARMACEUTICALS](#)

MGC says it has begun a 150-patient pilot study into the effectiveness and safety of Artemic for “long Covid”.

NEUROSCIENTIFIC: ‘EMTIN PEPTIDES MODULATE INFLAMMATION IN-VITRO’

[NEUROSCIENTIFIC BIOPHARMACEUTICALS](#)

Neuroscientific says its Emtinac, Emtinan, and Emtinbn peptide candidates modulated key inflammatory targets in cell-based assays.

NIV DAGAN TAKES 11.38% OF INHALERX

[INHALERX](#)

Niv Dagan, Freedom Trader and 10 Bolivianos say they have increased their holding in Inhalerx from 14,901,280 shares (8.85%) to 19,172,302 shares (11.38%).

TOTAL BRAIN PAYS \$3.1m FOR JANSSEN DEPRESSION RESEARCH

[TOTAL BRAIN](#)

Total Brain says it will pay Janssen Research & Development \$US2.2 million (\$A3.1 million) for perpetual, non-exclusive rights to its depression research data. Total Brain said the Raritan, New Jersey-based Janssen would share data from its International Study to Predict Optimized Treatment for Depression, effective immediately.

Wednesday December 22, 2021

ANTISENSE SHARE PLAN RAISES \$2.6m; TOTAL \$22.6m

[ANTISENSE THERAPEUTICS](#)

Antisense says it raised \$2,586,504 in a share plan, which combined with a recent placement, raised a total of \$22,586,503.

CYNATA STARTS PHASE I CYP-006TK DIABETIC FOOT ULCER TRIAL

[CYNATA THERAPEUTICS](#)

Cynata says it has begun a 30-patient, randomized, 24-week, phase I trial comparing its CYP-006TK to standard-of-care for diabetic foot ulcers.

PLATINUM INCREASES, DILUTED TO 15% OF AMPLIA

[AMPLIA THERAPEUTICS](#)

Platinum Investment Management says it has increased and been diluted in Amplia from 27,018,000 shares (17.45%) to 34,813,002 shares (14.97%).

DIMERIX RECEIVES FEDERAL \$100k GRANT

[DIMERIX](#)

Dimerix says it received \$100,000 from the Federal Government’s Medical Research Future Fund to support commercialization of DXB-200 for Covid-19.

PLATINUM TAKES 17% OF ADALTA

[ADALTA](#)

Platinum Investment Management says it has increased its holding in Adalta from 25,000,067 shares (12.26%) to 49,048,028 shares (16.51%).

AUSTRALIAN SUPER TAKES 9.5% OF ALCIDION

[ALCIDION](#)

Australian Super says it has increased its holding in Alcidion from 52,491,042 shares (5.05%) to 110,991,042 shares (9.5%).

MICRO-X RECEIVES \$2.1m R&D TAX INCENTIVE

[MICRO-X](#)

Micro-X says it received a \$2,079,450 research and development tax incentive from the Australian Tax Office for the financial year ended June 30, 2021.

RESAPP APPOINTS SANRAI 'EMERGING MARKETS' DISTRIBUTOR

[RESAPP HEALTH](#)

Resapp says it has signed a three-year distribution agreement with the New York-based Sanrai International for Resappdx "in emerging markets".

SIO INCREASES, DILUTED TO 12.6% OF ANTERIS

[ANTERIS TECHNOLOGIES](#)

Sio Capital and related funds say they have increased and been diluted in Anteris from 1,262,680 shares (14.38%) to 1,274,966 shares (12.61%).

FIL BELOW 5% OF COGSTATE

[COGSTATE](#)

FIL Investment says it has ceased its substantial holding in Cogstate, selling 1,293,441 shares at prices from \$1.6979 to \$2.4337, reducing to 8,556,049 shares (4.96%).

MARK LAMPERT, BVF INCREASE, DILUTED TO 13% OF BIONOMICS

[BIONOMICS](#)

Mark Lampert and BVF Partners say they have increased and been diluted in Bionomics from 155,517,432 shares (15.49%) to 170,089,885 shares (12.99%).

SHENGLI WANG DILUTED TO 10.63% OF INVION

[INVION](#)

Shengli Wang and associates say their 681,440,371 share-holding in Invion has been diluted from 12.31 percent to 10.63 percent.

LUMOS VIRADIX RAPID TEST SUBMISSIONS READY; ELLERSTON BELOW 5%

[LUMOS DIAGNOSTICS](#)

Lumos says it has completed development on its Viradx rapid antigen test for severe acute respiratory syndrome coronavirus-2 (Sars-Cov-2), influenza A and influenza B. Lumos said that a US Food and Drug Administration Viradx submission was underway. Ellerston Capital said it had ceased its substantial holding, selling 1,326,352 shares.

REGENEUS \$800k R&D INCENTIVE; JAPAN PROGENZA PATENT

[REGENEUS](#)

Regeneus says it received a \$830,000 research and development tax incentive from the Australian Tax Office for the financial year ended June 30, 2021.

Regeneus said that the Japan Patent Office had granted a further patent protecting its Progenza cell therapy for pain and inflammation until 2036.

The company also said that it had terminated its placement agreement with New Life Sciences in order to explore non-dilutive funding options.

ANTEOTECH RECEIVES \$1.96m R&D TAX INCENTIVE

[ANTEOTECH](#)

Anteotech says it received a \$1,965,463 research and development tax incentive from the Australian Tax Office for the financial year ended June 30, 2021.

EXOPHARM US PATENT FOR LEAP EXOSOME PRODUCTION

[EXOPHARM](#)

Exopharm says the US Patent and Trademark Office has granted a patent for its ligand-based exosome affinity purification (Leap) exosome production system. Exopharm said the patent was titled 'Methods And Compositions For Purification Or Isolation Of Microvesicles And Exosomes' but did not state the patent duration.

NYRADA PHASE I CHOLESTEROL DRUG TRIAL IN LATE-2022

[NYRADA](#)

Nyrada says it will begin a 56-volunteer, phase I trial of its cholesterol drug candidate in late 2022, following pre-clinical safety studies in the US early next year.

Nyrada said the phase I trial would be the first-in human double-blind, randomized, dose escalation study of its leading drug candidate.

Thursday December 23, 2021

AVITA AGM: 42% OPPOSE EXECUTIVE COMPENSATION

[AVITA MEDICAL](#)

Avita says that 41.65 percent of votes cast at its shareholder meeting opposed a resolution seeking approval for the compensation of the company's executives. Avita said resolutions proposing the issue of stock and options to directors Louis Panaccio, Prof Suzanne Crowe, Jeremy Curnock-Cook, Louis Drapeau, James Corbett, Jan Stern Reed, and chief executive officer Michael Perry were opposed by more than 20 percent of votes.

The company said that a resolution to increase its non-executive director pay pool from \$US600,000 (\$A831,000) to \$750,000 (\$A 1,040,000) faced 23.56 percent opposition. Avita has the equivalent of 24,926,118 US shares on offer, meaning that the largest vote against the resolutions amounted to 18.97 percent of the company.

DIMERIX APPROVAL FOR AUSTRALIAN PILOT/PHASE III COVID STUDY

[DIMERIX](#)

Dimerix says it has Australian approval for a 26-week multi-centre, randomized, double blind, placebo-controlled feasibility/phase III study of DMX-200 for Covid-19.

In September, Dimerix said India had recommended approval of its proposed 660-patient phase III trial of DMX-200 for Covid-19 (BD: Sep 24, 2021).

NUHEARA \$4.6m PLACEMENT, RIGHTS OFFER FOR \$3m

[NUHEARA](#)

Nuheara says it has commitments to raise \$4.6 million in a placement and hopes to raise \$3 million more in share purchase plan.

Nuheara said the price of the shares in the placement and share plan would be decided at a later date, but would be between one and six cents a share.

The company said the capital raising would support further growth, and a 510(k) submission to the US Food and Drug administration.

PERENNIAL REDUCES TO 7.55% OF MEDADVISOR

[MEDADVISOR](#)

Perennial Value Management says it has reduced its substantial holding in Medadvisor from 33,392,668 shares (8.85%) to 28,518,170 shares (7.55%).

RESPIRI, M-TELEHEALTH SIGN 5-YEAR, \$210k DEAL FOR WHEEZO IN THE US

[RESPIRI](#)

Respiri says it has a five-year, 1,000 unit-per-quarter deal worth \$208,000 initially with the Delray Beach, Florida-based M-telehealth to sell its Wheezo platform in the US.

Friday December 24, 2021 (Christmas Eve)

ONCOSIL: LOCAL PANCREATIC CANCER CONTROL IN 90.5% OF PATIENTS

[ONCOSIL MEDICAL](#)

Oncosil says a study of its radioactive nano-particles for pancreatic cancer showed local disease control in 38 of 42 (90.5%) of treated patients.

YUUWA DILUTED TO 18.2% OF ADALTA

[ADALTA](#)

Yuuwa Capital says its substantial holding of 54,059,848 shares in Adalta has been diluted from 22.05 percent to 18.2 percent.

INOVIQ (BARD1): CHINA PATENT FOR LUNG CANCER DIAGNOSIS

[INOVIQ \(FORMERLY BARD1 LIFESCIENCE\)](#)

Inoviq says the China Patent Office has granted a patent, titled 'Lung Cancer Diagnosis', protecting the technology until February 5, 2035.

UNIVERSAL BIOSENSORS \$50k PA FOR IQ SCIENCE APTAMERS

[UNIVERSAL BIOSENSORS](#)

Universal Biosensors says it will pay IQ Science \$50,000 a year for its aptamers in a severe acute respiratory syndrome coronavirus-2 (Sars-Cov-2) test. Universal Biosensors said it would pay the Wellington, New Zealand-based IQ Science pre-commercialization fees until it received regulatory approval for the test or generated \$1 million of sales.

PARADIGM 2nd STRIKE, 80% DIRECTORS FEEL POOL HIKE; 525k SHARES

[PARADIGM BIOPHARMACEUTICALS](#)

Paradigm says investors will vote on a potential remuneration second strike, to increase non-executive director pay by 80 percent and issue 525,000 director shares. Paradigm said its annual general meeting would vote to increase the maximum pay pool from \$500,000 to \$900,000 a year and issue 450,000 shares to chair Paul Rennie and 375,000 shares to executive director Dr Donna Skerrett.

CITIGROUP TAKES 22.3% OF BIONOMICS

[BIONOMICS](#)

Citigroup Global Markets Australia says it has become substantial in Bionomics with 291,960,000 shares (22.2946%)

Citigroup Global Markets Australia said that it held a relevant interest in the shares as a depositary bank for American depositary receipts.

PERENNIAL TAKE 11.5% OF LUMOS

[LUMOS DIAGNOSTICS](#)

Perennial Value Management says it has increased its substantial holding in Lumos from 15,337,608 shares (10.21%) to 17,328,013 shares (11.52%).

STEMCELL FURTHER EXTENDS 'JOINT VENTURE' SUSPENSION

[STEMCELL UNITED](#)

Stemcell has requested a further extension to January 14, 2022 of the voluntary suspension it requested in September, pending a joint venture announcement.

ANDREW CHAPMAN, MERCHANT BELOW 5% OF RACE

[RACE ONCOLOGY](#)

After the market closed on Christmas Eve, Andrew Chapman and Merchant Funds said they had ceased to be substantial in Race Oncology.

Mr Chapman and Merchant funds said that between March 11 and December 21, 2021, they bought 824,800 shares for \$2,922,568 or an average of \$3.543 a share, and sold 2,209,532 shares for \$8,009,173 or an average \$3.625 a share, and were diluted in a share plan issue.

Biotech Daily calculates that Merchant retains 7,085,268 shares or 4.44 percent of the company.

Monday December 27, Tuesday December 28, 2021

ASX closed for Christmas, Boxing Day

Wednesday December 29, 2021

CYNATA, FUJIFILM MANUFACTURING DEAL

[CYNATA THERAPEUTICS](#)

Cynata says that Fujifilm Cellular Dynamics will manufacture and supply its Cymerus therapeutic mesenchymal stem cell products, triggering a 12-month extension on the voluntary escrow of 8.1 million shares held by Fujifilm Corp.

ALCIDION RIGHTS RAISE \$11.6m; TOTAL \$55m

[ALCIDION](#)

Alcidion says it has raised \$11.6 million in a one-for-10.5 retail rights offer at 25 cents a share, and with the recent placement takes the total raising to \$55 million.

ANTERIS OPTIONS RAISE \$18.9m

[ANTERIS TECHNOLOGIES](#)

Anteris says that the exercise of 2,370,209 listed options expiring on December 18, 2021 raised \$18,961,672.

LBT ACQUIRES HETTICH'S 50% OF CLEVER CULTURE SYSTEMS

[LBT INNOVATIONS](#)

LBT says it will pay the Westphalia, Germany-based Hettich GmbH \$4 million for its 50 percent of Clever Culture Systems, taking full ownership of the joint venture.

LBT said \$1 million would be paid in cash and the remaining \$3 million as 30.66 million shares and eight million options.

OSTEOPORE: MARK LEONG EXECUTIVE CHAIR; VLADO BOSANAC DIRECTOR
[OSTEOPORE](#)

Osteopore says chair Mark Leong will be promoted to executive chair, and that Vlado Bosanac will become a director.

LIVING CELL RIGHTS RAISE \$361k; \$3.4m SHORTFALL

[LIVING CELL TECHNOLOGIES](#)

Living Cell says its rights issue raised \$361,264 with \$250,000 in expenses, and 180 Markets Pty Ltd would attempt to place the \$3,445,942 “on a best endeavours basis”.

CANN GLOBAL AGM: \$312k SHARES FOR EX-CHAIR PNINA FELDMAN

[CANN GLOBAL](#)

Cann Global says its annual general meeting will vote to issue \$312,000 worth of shares to former executive chair Pnina Feldman.

The meeting will be held virtually at 10am (AEST) on January 21, 2022.

CARL CHARALAMBOUS TAKES 7.23% OF EXOPHARM

[EXOPHARM](#)

Carl Charalambous says he has increased his substantial holding in Exopharm from 8,653,912 shares (6.21%) to 11,371,818 shares (7.23%).

DARRYL DAVIES REPLACES INHALERX CEO MATTHEW GOLDEN

[INHALERX](#)

Inhalerx says chief executive officer Matthew Golden has resigned, and it has appointed Darryl Davies as executive director, effective immediately.

EX-DIRECTOR BERNARD HOCKINGS REDUCES TO 6.3% OF PYC

[PYC THERAPEUTICS](#)

Former PYC director Bernard Hockings says he has reduced his substantial holding from 262,835,396 shares (8.3%) to 199,835,396 shares (6.3%).

TOTAL BRAIN \$692k ALTO NEUROSCIENCE ISPOT-D DATA DEAL

[TOTAL BRAIN](#)

Total Brain says Alto Neuroscience will pay \$US500,000 (\$A692,000) for its Ispot-D (international study to predict optimized treatment for depression) research data.

Total Brain said that the Los Altos, California-based Alto Neuroscience would pay \$US100,000 for the licence fee and \$US400,000 within 15 days of the data transfer date, expected by March 31, 2022.

Thursday December 30, 2021

RESONANCE FDA CLEARANCE FOR LIVERSMART

[RESONANCE HEALTH](#)

Resonance says it has received clearance from the US Food and Drug Administration for its artificial intelligence-enabled Liversmart magnetic resonance imaging (MRI) test. Resonance said Liversmart might be eligible for two category III current procedural technology (CPT) codes, holding the potential for government reimbursement.

ATOMO PLEADS SCHULTZ, MEDIA, RATS TO ASX 36% PRICE QUERY

[ATOMO DIAGNOSTICS](#)

Atomo has told the ASX that it is not aware of any information it has not announced which, if known, could explain recent trading in its securities.

The ASX said the company's share price increased 35.7 percent from 21 cents on December 24 to a high of 28.5 cents on December 29, 2021, and noted a "significant" increase in trading volume.

Atomo told the ASX that articles on rapid antigen tests (RATs) might have contributed to the price rise.

ASIA PACIFIC HEALTHCARE INVESTMENTS TAKES 6% OF CLARITY

[CLARITY PHARMACEUTICALS](#)

Asia Pacific Healthcare Investments says it has become a substantial shareholder in Clarity with 15,362,700 shares or 6.00 percent of the company.

TRAJAN PAYS \$7m, 4.7m SHARES FOR NEOTERYX BLOOD MICRO-SAMPLING

[TRAJAN](#)

Trajan says it has paid \$US5.05 million (\$A6.96 million) and 4,659,843 shares for the Torrance, California-based blood micro-sampling company Neoteryx.

Trajan said the agreement included a requirement for Neoteryx's parent company Farrona to hold its shares in voluntary escrow for six months.

EMYRIA APPOINTS SIXTY TWO CAPITAL ADVISER

[EMYRIA](#)

Emyria says it has appointed Perth's Sixty Two Capital Pty Ltd as a corporate adviser and will pay it \$120,000 over the next 12 months and issue 6,000,000 performance-based options, exercisable at 55 cents each within two years.

Friday December 31, 2021 (New Year's Eve)

MESOBLAST TO FILE NEW REMESTEMCEL-L POTENCY DATA TO FDA

[MESOBLAST](#)

Mesoblast says a US Food and Drug Administration department has agreed its approach to outstanding remestemcel-L quality issues is "reasonable".

Mesoblast said that the Office of Tissues and Advanced Therapies "indicated that [its] approach to address the outstanding [chemistry, manufacturing and controls] items is reasonable" for remestemcel-L for children with acute graft-versus-host disease.

The company said it would file new data in support of its application for approval.

TRAJAN COMPLETES LEAP ACQUISITION

[TRAJAN](#)

Trajan says it has completed its acquisition of the Raleigh, North Carolina-based Leap Pal Parts and Consumables.

PERENNIAL BELOW 5% IN NUHEARA

[NUHEARA](#)

Perennial says it has ceased to be substantial in Nuheara, selling more than 11 million shares in the company.

BIONOMICS LOSES BVF PARTNERS NOMINEE DIRECTOR MITCHELL KAYE

[BIONOMICS](#)

Bionomics says director Richard Kaye resigned today as a director under its placement agreement with the San Francisco-based BVF Partners.

ECOFIBRE EXTENDS LOAN TERMS

[ECOFIBRE](#)

Ecofibre says the amount of its \$10 million loan at 8.0 percent a year, to be repaid on July 15, 2022 has been reduced to \$2 million, with the balance due on July 15, 2023.

M-D ROBERT WONG TAKES 6.79% OF CONTROL BIONICS

[CONTROL BIONICS](#)

After the market closed for New Year's Eve, Control Bionics managing-director Robert Wong says he has become a substantial shareholder with 5,906,294 shares (6.79%).

Monday January 3, 2022

ASX closed for New Year's Day public holiday

Tuesday January 4, 2022

OPTHEA APPOINTS EX-DIRECTOR JUDITH ROBERTSON CCO

[OPTHEA](#)

Opthea says it has appointed Judith Robertson chief commercial officer to lead commercialization of OPT-302 for wet age-related macular degeneration. Opthea said Ms Robertson would resign as a director to focus on the role.

IMUGENE COMPLETES PHASE Ia PD1-VAXX MONOTHERAPY DOSING

[IMUGENE](#)

Imugene says it has completed the monotherapy stage of phase I dose escalation of PD1-Vaxx for non-small cell lung cancer, with the trial showing "early efficacy signals". Imugene said it was finalizing plans to combine PD1-Vaxx with Roche-Genentech's atezolizumab (Tecentriq) for the phase Ib portion of the study.

IMUGENE APPOINTS URSULA MCCURRY, DR NIMALI WITHANA EXECUTIVES

[IMUGENE](#)

Imugene says it has appointed former Roche-Genentech employees Ursula McCurry head of clinical operations and Dr Nimali Withana head of clinical science.

ALTERITY LOSES DIRECTORS DR DAVID SINCLAIR, TRISTAN EDWARDS

[ALTERITY THERAPEUTICS](#)

Alterity says that directors Dr David Sinclair and Tristan Edwards have resigned with immediate effect "due to competing priorities".

HETTICH TAKES 9.6% OF LBT

[LBT INNOVATIONS](#)

The Westphalia, Germany-based Hettich Holding Beteiligungs-und Verwaltungs-GmbH says it has become substantial in LBT with 30,660,377 shares (9.6%).

BIONOMICS STARTS PHASE II BNC-210 SOCIAL ANXIETY TRIAL

[BIONOMICS](#)

Bionomics says it has begun its phase II study of BNC-210 for acute treatment of social anxiety disorder, with topline results expected by the end of 2022.

CHRISTIAN ANGEMAYER, APEIRON TAKE 19.9% OF BIONOMICS

[BIONOMICS](#)

Christian Angemayer and Apeiron Investment say they have increased their holding in Bionomics from 123,240,066 shares (12.28%) to 260,550,387 shares (19.9%).

HEXIMA APPOINTS PHILLIP ROSE US CHIEF COMMERCIAL OFFICER

[HEXIMA](#)

Hexima says it has appointed Phillip Rose as US-based chief commercial officer.

IMRICOR: ATHENS' HENRY DUNANT HOSPITAL BUYS ABLATION PRODUCTS

[IMRICOR](#)

Imricor says it will supply its interventional cardiac magnetic resonance ablation technology to the Athens, Greece-based Henry Dunant Hospital Centre.

ISLAND HIRES ICON FOR PHASE II ISLA-101 DENGUE FEVER TRIAL

[ISLAND PHARMACEUTICALS](#)

Island says it has that Dublin's Icon Government and Public Health Solutions will conduct its phase II trial of ISLA-101 for Dengue fever.

Wednesday January 5, 2022

ANTERIS APPLIES FOR ADAPT STERILISATION PATENT

[ANTERIS TECHNOLOGIES](#)

Anteris says it has applied for a patent protecting its Adapt sterilization technology as part of its manufacturing process for its Duravr aortic valve replacement.

Anteris did not state the jurisdiction of potential duration of the patent application.

CRONOS PLEADS SCHULTZ, 'CDA MERGER TO ASX 42% PRICE QUERY

[CRONOS AUSTRALIA](#)

Cronos has told the ASX that it is not aware of any information it has not announced which, if known, could explain recent trading in its securities.

The ASX said the company's share price rose 42.2 percent from 23 cents on January 4 to 32.7 cents on January 5, 2022 and noted a "significant" increase in the trading volume.

Cronos said its merger with CDA Health "may have contributed to the recent increase in the company's share price and trading volumes" (BD: Dec 16, 2021).

DR GISELA MAUTNER REPLACES NOXOPHARM CEO, M-D DR GRAHAM KELLY

[NOXOPHARM](#)

Noxopharm says chief medical officer Dr Gisella Mautner will replace Dr Graham Kelly as chief executive officer and managing director, effective from February 1, 2022.

Noxopharm said that Dr Kelly would continue as a director.

Thursday January 6, 2022

PHARMAXIS: NHMRC \$1.4m FOR DRUG PIPELINE RESEARCH

[PHARMAXIS](#)

Pharmaxis says the National Health and Medical Research Council has granted \$1.4 million to research teams conducting work on Pharmaxis drug candidates. Pharmaxis said that Sydney's Garvan Institute of Medical Research's Prof Thomas Cox had been awarded \$827,500 to investigate PXS-5505 for pancreatic cancer. The company said that the University of Western Australia's Prof Fiona Wood and Prof Mark Fear had been awarded \$590,200 for work on its serine protease inhibitor as a potential treatment from tissue repair and inflammatory skin disease.

ALTERITY: US PATENT FOR NEURO-DEGENERATIVE DISEASE

[ALTERITY THERAPEUTICS](#)

Alterity says the US Patent and Trademark Office has granted it a patent titled 'Compounds for and Methods of Treating Diseases', protecting it until 2041. Alterity said it would cover more than 80 novel compounds including its iron chaperones designed to redistribute excess iron implicated in many neuro-degenerative diseases, including Parkinson's and Alzheimer's diseases.

IMUGENE: SOUTH KOREA PATENT FOR HER-VAXX

[IMUGENE](#)

Imugene says that South Korea has granted a HER-Vaxx-related patent titled 'A Vaccine Composition And Uses Thereof' and providing protection until 2036.

NUHEARA COMPLETES HEARING AID CLINICAL TRIAL

[NUHEARA](#)

Nuheara says it has completed a clinical trial of its hearing aid, with all participant data collected and a final trial report expected by the end of January.

RHYTHM: \$6.53m PLACEMENT TO UNNAMED 'GLOBAL FUNDS MANAGER'

[RHYTHM BIOSCIENCES](#)

Rhythm says it has raised \$6,532,651 through a placement, at \$1.40 a share, to an unnamed "global institutional funds manager".

CITIGROUP TAKES 24.73% OF BIONOMICS

[BIONOMICS](#)

Citigroup Global Markets Australia says it has increased its substantial holding in Bionomics from 291,960,000 (22.2946%) to 334,683,720 (24.73%). Citigroup said it held the shares as "acting as depository for American depository receipts programs".

Friday January 7, 2022

IMUGENE RECEIVES \$6.54m FEDERAL R&D TAX INCENTIVE

[IMUGENE](#)

Imugene says it has received \$6,541,921 from the Australian Tax Office under the Federal Government Research and Development Tax Incentive program. Acrux said the rebate related to expenditure for the year to June 30, 2021.

FEDERAL \$15m FOR PSYCHEDELICS FOR MENTAL HEALTH

[FEDERAL GOVERNMENT](#)

The Federal Government says it has granted \$14.8 million for seven mental health trials of using a range of psychedelic drugs.

A media release for Federal Health Minister Greg Hunt said that the Medical Research Future Fund would provide the funds for the use of 3,4-methylene-dioxy-methamphetamine (MDMA or ecstasy), psilocybin, dimethyl-tryptamine and cannabidiol for conditions including major depression with alcohol use, anorexia nervosa, post-traumatic stress disorder (PTSD) and anxiety disorders.

ISRAEL'S REDHILL APPOINTS GAELAN EMIRATES TALICIA DISTRIBUTOR

[REDHILL BIOPHARMA](#)

Israel's Redhill says Gaelan Medical will pay \$US2 million (\$A2.8 million) upfront to distribute Talicia for Helicobacter pylori in the United Arab Emirates.

In 2010, Redhill bought Heliconda (RHB-105) from Sydney's Giaconda, which it developed into Talicia (BD: Aug 17, 2010).

AVITA: 'PROOF-OF-CONCEPT FOR GM SKIN CELLS'

[AVITA MEDICAL](#)

Avita says it has shown proof-of-concept for its genetically modified Spray-On skin for the treatment of epidermolysis bullosa and for skin rejuvenation.

Avita said the skin rejuvenation study at Houston Methodist Research Institute showed successful regeneration in combination with Houston Medical's RNA technologies.

The company said the epidermolysis bullosa study took place at the Gates Center for Regenerative Medicine at the University of Colorado School of Medicine, and showed successful regeneration of skin cells without the associated mutation.

AVITA: RECELL SOFT-TISSUE RECONSTRUCTION TRIAL ENROLLED

[AVITA MEDICAL](#)

Avita says it has completed patient enrolment for a trial of its Recell cell-therapy for soft-tissue reconstruction.

MESOBLAST: 1.7m US WARRANTS FOR OAKTREE LOAN FACILITY

[MESOBLAST](#)

Mesoblast says it will issue Los Angeles' Oaktree Capital 1,769,669 warrants exercisable at \$US7.26 (\$A10.08) each in refinancing a \$US90 million loan facility.

The warrants are equivalent to 8,848,345 Australian options exercisable at \$A2.016 each, within seven years of issue.

RESAPP: RESAPPDX ON ALODOKTER TELEHEALTH PLATFORM

[RESAPP HEALTH](#)

Resapp says its Resappdx acute respiratory test has been implemented on the Jakarta, Indonesia-based Alodokter telehealth platform.

RECCE: POSITIVE SAFETY DATA FROM PHASE I R327 TRIAL

[RECCE PHARMACEUTICALS](#)

Recce says it has positive safety data from the first patient cohort of nine healthy males in a phase I trial for its R327 antibiotic, and had met all end-points.

Recce said an independent safety committee had approved a threefold increase (from 50mg to 150mg) among the subjects.

CRESO TO RELEASE 47m SHARES FROM VOLUNTARY ESCROW

[CRESO PHARMA](#)

Creso says that 46,802,872 shares owned by the vendors of Halucenex Life Sciences will be released from voluntary escrow on January 14, 2022.

MGC: INDIA GRANTS ARTEMIC RESCUE IMPORT APPROVAL

[MGC PHARMA](#)

MGC says India has approved the importation and distribution of its Artemic rescue Covid-19 treatment.

NOXOPHARM RECEIVES \$5.9m FEDERAL R&D TAX INCENTIVE

[NOXOPHARM](#)

Noxopharm says it has received \$5,865,029 from the Australian Tax Office under the Federal Government Research and Development Tax Incentive program. Acrux said the rebate related to expenditure for the year to June 30, 2021.

Monday January 10, 2022

PHARMAXIS TELLS ASX: 'NHMRC GRANTS NOT MATERIAL'

[PHARMAXIS](#)

Pharmaxis has told an ASX 'aware' query that its announcement regarding NHMRC grants to third party researchers totalling \$1.4 million was "not price sensitive". Pharmaxis said the announcement had been marked price sensitive "based on an incorrect understanding of recent ASX guidance".

GENETIC SIGNATURES: TGA REGISTERS SARS-CoV-2 SALIVA PROTOCOL

[GENETIC SIGNATURES](#)

Genetic Signatures says that the Australian Therapeutic Goods Administration has registered its saliva-based protocol for collecting and testing SARS-CoV-2 samples. Genetic Signatures said the protocol followed a study showing that the Omicron variant was associated with a higher viral RNA load in the saliva than in nasal samples.

RESAPP COMPLETES US COVID-COUGH STUDY RECRUITMENT

[RESAPP HEALTH](#)

Resapp says it has collected cough recordings and self-reported symptoms for 122 polymerase chain reaction (PCR) severe acute respiratory syndrome coronavirus-2 (Sars-Cov-2) confirmed cases, as well as 139 PCR-confirmed negative cases for its US Covid-cough study.

The company said that the pilot trial aimed "to collect data to train an algorithm to identify Covid-19 [Sars-Cov-2] through cough sounds recorded on a smartphone, using a gold standard PCR pathology test as a reference standard".

INOVIQ \$89k FOR SUBB2M TEST ANTIBODIES

[INOVIQ \(FORMERLY BARD1 LIFESCIENCES\)](#)

Inoviq says it has received an additional \$89,331 from MTP Connect's Biomedical Translation Bridge (BTB) program for its SubB2M immunoassay antibodies.

CHELSEA SHERIDA REPLACES BLUECHIIP CO SEC LEE MITCHELL

[BLUECHIIP](#)

Bluechiip says it has appointed the Melbourne-based Automic Group's Chelsea Sheridan as company secretary following the resignation of Lee Mitchell.

RACE CHAIR DR JOHN CULLITY SELLS 300k SHARES

[RACE ONCOLOGY](#)

Race says that chair Dr John Cullity has sold 300,000 shares for \$995,174, 200,000 of which were placed with long-term shareholders and 100,000 sold on-market.

Race said Dr Cullity sold the shares to cover personal and tax commitments, held 8,102,194 shares and had committed to no further sales over the next 12 months.

ZELIRA RECEIVES \$348k FROM DRCN

[ZELIRA THERAPEUTICS](#)

Zelira says it has received \$US250,000 (\$A348,000) of an expected \$US1 million (\$A1.4 million) fee from DCRN holdings for its cannabinoid distillate technology.

Zelira said it expects the remaining funds by the end of March.

Tuesday January 11, 2022

POLYNOVO H1 REVENUE UP 43% TO \$18.04m

[POLYNOVO](#)

Polynovo says its unaudited revenue for the six months to December 31, 2021, was up 43 percent to \$18.04 million.

DIMERIX DOSES 1st DMX-200 COVID-19 PATIENTS IN INDIA

[DIMERIX](#)

Dimerix says it has dosed its first patients in a phase III trial of DMX-200 for Covid-19 in India, with Australian recruitment and dosing expected to commence this month.

KIM BRADLEY REPLACES CRYOSITE CHAIR BRYAN DULHUNTY AS CO SEC

[CRYOSITE](#)

Cryosite says chair Bryan Dulhunty has resigned as company secretary, and will be replaced in the role by Kim Bradley, effective immediately.

CRESO: HALUCENEX APPLIES FOR CANADA SPECIAL ACCESS PROGRAM

[CRESO PHARMA](#)

Creso says subsidiary Halucenex will apply to become a supplier to Canada's special access program, which provides restricted drugs for medical treatment.

BCAL APPOINTS DR JOHN HURRELL CEO; STARTS ON \$300k

[BCAL DIAGNOSTICS](#)

BCal says it has appointed former Quest Diagnostics executive Dr John Hurrell as its chief executive officer, starting on \$300,000 a year, plus incentives.

BLACKROCK TAKES 12.2% OF IMRICOR

[IMRICOR MEDICAL SYSTEMS](#)

The New York and Sydney-based Blackrock Group says it has increased its holding in Imricor from 15,788,844 shares (11.08%) to 17,529,397 shares (12.23%).

SDI H1 REVENUE UP 26% TO \$46m

[SDI \(FORMERLY SOUTHERN DENTAL INDUSTRIES\)](#)

SDI says its total revenue for the six months to December 31, 2021, was up 26 percent to \$46.2 million.

Wednesday January 12, 2022

COMPUMEDICS H1 ORDERS UP 33%, REVENUE DOWN 7% TO \$17m

[COMPUMEDICS](#)

Compumedics says unaudited revenue for the six months to December 31, 2021 is forecast to fall seven percent to \$17 million due to “global supply issues”.

Compumedics said this was despite record sales up 33 percent on the previous year to \$27 million.

COMPUMEDICS \$4.2m ORION LIFESPAN SALE TO TIANJIN NORMAL UNI

[COMPUMEDICS](#)

Compumedics says it has sold an Orion Lifespan magneto-encephalo-graphy (MEG) system to China’s Tianjin Normal University for \$4.2 million, its largest contract to date. Compumedics said the hardware would be specially configured to allow the study of two subjects simultaneously.

MESOBLAST: REXLEMESTROCEL-L PROVIDES 3-YEAR LOWER BACK RELIEF

[MESOBLAST](#)

Mesoblast says 36-month follow-up results of its 404-patient phase III trial of rexllestrocel-L for chronic lower back pain show durable pain reduction.

KKR CORE INVESTORS TAKES 6% OF CLARITY

[CLARITY PHARMACEUTICALS](#)

KKR Core Investors and associated funds say that they have become substantial in Clarity with 15,362,700 shares (6.00%).

IMMURON: \$6.2m FOR US MILITARY-GRADE TRAVELAN FOR DIARRHOEA

[IMMURON](#)

Immuron says it has received \$4.45 million (\$6.2 million) from the US Department of Defence for the development of a military dosing regimen of Travelan for diarrhoea. Immuron said plans were in place for a 60-volunteer controlled human infection model clinical trial in the US.

LIVERPOOL PHARMACIES ADOPT LUMOS FEBRIDX

[LUMOS DIAGNOSTICS](#)

Lumos says that more than 100 Liverpool UK pharmacies will use its 10-minute Febridx diagnostic to differentiate between bacterial and viral respiratory infections.

ZELIRA RECEIVES \$1.2m FEDERAL R&D TAX INCENTIVE

[ZELIRA THERAPEUTICS](#)

Zelira says it has received \$1,292,000 from the Australian Tax Office under the Federal Government Research and Development Tax Incentive program. Zelira said the rebate related to expenditure for the year to June 30, 2021.

MAYNE TO SELL GENERIC PROTOPIC FOR ECZEMA IN US

[MAYNE PHARMA](#)

Mayne Pharma says it will distribute tacrolimus ointment, 0.1%, or generic Protopic, for atopic dermatitis, or eczema, to its US dermatology portfolio.

NYRADA RECEIVES \$1.3m FEDERAL R&D TAX INCENTIVE

[NYRADA](#)

Nyrada says it has received \$1,309,650 from the Australian Tax Office under the Federal Government Research and Development Tax Incentive program.

Nyrada said the rebate related to expenditure for the year to June 30, 2021.

Thursday January 13, 2022

FEDERAL \$25.6m FOR CYNATA, ACRUX, AXIAL

[FEDERAL GOVERNMENT](#)

The Federal Government says its Biomedical Translation Fund will provide \$25.6 million to Cynata, Acrux and Axial Therapeutics.

The Federal Government said Cynata would receive \$10 million to support the large-scale manufacture of stem cells, Acrux would receive \$5 million to develop transdermal drugs, with \$10.6 million for the Woburn, Massachusetts-based Axial Therapeutics to support microbiome-gut-brain treatments for neurological disorders.

PARADIGM DOSES 1st PHASE III OSTEO-ARTHRITIS PPS PATIENTS

[PARADIGM BIOPHARMA](#)

Paradigm says it has dosed the first two of 930 patients in its randomized, double-blind, placebo-controlled phase III trial of zilosul for knee osteo-arthritis.

Paradigm said the trial would “measure the change in pain and function with subcutaneous injections of [zilosul or injectable pentosan polysulfate sodium] compared with ... placebo”, beginning with a dose selection phase.

AMPLIA COMPLETES AMP945 MANUFACTURE FOR TRIALS

[AMPLIA THERAPEUTICS](#)

Amplia says it has completed manufacture of AMP945 for toxicology studies and two phase II trials for pancreatic cancer and lung fibrosis.

ADHERIUM: US FINALISES REMOTE THERAPEUTIC MONITORING CPT CODES

[ADHERIUM](#)

Adherium says the United States Centres for Medicare & Medicaid Services has finalised its Current Procedural Terminology codes for remote therapeutic monitoring.

IMMURON: EU PATENT FOR TRAVELLER'S DIARRHOEA

[IMMURON](#)

Immuron says it has received a patent from European Patent Office protecting its compositions and methods for treating travellers' diarrhoea.

Immuron said that the patent was titled ‘Composition and method for the treatment and prevention of enteric bacterial infections’ but did not provide its duration.

ARGENICA APPOINTS DR MEGHAN THOMAS CLINICAL DEVELOPMENT HEAD
[ARGENICA THERAPEUTICS](#)

Argenica says it has appointed Dr Meghan Thomas head of clinical development beginning early April, and will oversee its phase I trial of ARG-007 for stroke.

ARTRYA APPOINTS DR JACQUE SOKOLOV ADVISOR BOARD CHAIR

[ARTRYA](#)

Artrya says it has appointed former US White House advisor Dr Jacque Sokolov chair of its clinical advisory board, awarding 3.9 million options exercisable at \$5.00 each.

KOSMAS DIMITRIOU REPLACES IQ3 CO SEC RON HOLLANDS

[IQ3 CORP](#)

Iq3corp says it has appointed Kosmas Dimitriou as company secretary following the resignation of Ron Hollands, both effective immediately.

KORDA MENTHA REQUESTS BIDS FOR PALLA

[PALLA PHARMA](#)

Korda Mentha, as administrator of Palla, says it will seek the recapitalization or sale of the company, and requests indicative offers by January 31, 2022.

Friday January 14, 2022

REDHILL: OPAGANIB IMPROVES COVID-19 VIRAL RNA CLEARANCE

[REDHILL BIOPHARMA](#)

Redhill says data from its 463-patient, phase II/III trial of opaganib for Covid-19 shows that the drug improves patients' median viral RNA clearance by at least four days. Redhill said the trial results were achieved in a "severely ill hospitalized patient population".

The company's chief scientific officer Dr Mark Levitt said "as opaganib's proposed mechanism of action targets a host factor, its activity is not expected to be affected by mutations in the spike protein emerging with new viral variants, including Omicron." Redhill said that post-study analysis of data from 251 study participants requiring oxygen for Covid-19 infection showed opaganib reduced mortality by 62 percent.

MTP CONNECT AWARDS 10 FELLOWHIPS

[MTP CONNECT](#)

MTP Connect says it has awarded 10 researcher fellowships of up to \$250,000 to supported by the Medical Research Future Fund.

MTP CONNECT: \$20m FOR DIABETES, CARDIOVASCULAR DISEASE

[MTP CONNECT](#)

MTP Connect says it will provide \$20 million to establish two research centres for diabetes and cardiovascular disease, with co-contributions totalling \$34 million. MTP Connect said the Medical Research Future Fund grants would assist 31 projects at the Australian Centre for Accelerating Diabetes Innovations led by the University of Melbourne and at the Australian Stroke and Heart Research Accelerator which brought together researchers from eight universities and research institutes.

CARDIEX 1-FOR-10 CONSOLIDATION EGM

[CARDIEX](#)

Cardiex says an extraordinary general meeting will vote to approve a 10-for-one consolidation of its shares and options.

Cardiex said the consolidation would reduce its shares on offer from 1,099,022,516 shares to 109,902,252 shares.

EVERCORE TAKES 22% OF BIONOMICS

[BIONOMICS](#)

Evercore Group LLC says it has become substantial in Bionomics with 287,960,738 shares or 21.99 percent of the company.

AROVELLA (SUDA) LOSES EXECUTIVE DIRECTOR DAVID PHILLIPS

[AROVELLA \(FORMERLY SUDA PHARMACEUTICALS\)](#)

In an Appendix 3Z final director's interest notice Arovella executive director David Phillips said he ceased to be a director on January 14, 2022.

Mr Phillips was appointed a director in 2018 (BD: Apr 9, 2018).

STEMCELL FURTHER EXTENDS 'JOINT VENTURE' SUSPENSION

[STEMCELL UNITED](#)

Stemcell has requested a further extension of the voluntary suspension it requested in September, pending a joint venture announcement to January 31, 2022.